Stocks TelegraphStocks Telegraph
Stock Ideas

ALLO Company Profile and Key Details

NASDAQ : ALLO

Allogene Therapeutics

$2.28
0.01000004+0.44%
At Close 4:00 PM
63.69
BESG ScoreESG Rating
ProfileKey StatsAnalyst RatingsOwnershipRatiosFinancialsDividend & splitsSentimentForecast

Price Chart

Stock Price Today

Allogene Therapeutics, Inc. (ALLO) stock surged +0.44%, trading at $2.28 on NASDAQ, up from the previous close of $2.27. The stock opened at $2.29, fluctuating between $2.25 and $2.36 in the recent session.

Stock Snapshot

2.27
Prev. Close
556.02M
Market Cap
2.25
Day Low
-2.62
P/E Ratio
-0.87
EPS (TTM)
-1.42
Cash Flow per Share
2.29
Open
243.87M
Number of Shares
2.36
Day High
74.36%
Free Float in %
3.04
Book Value
4.47M
Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing DateAccepted Date

Annual Report (10-k)

Filing DateAccepted Date

Stock Price History Chart

DateOpenHighLowCloseVolume
May 08, 20262.292.362.252.284.47M
May 07, 20262.322.362.252.275.67M
May 06, 20262.242.362.222.317.34M
May 05, 20262.292.332.142.175.81M
May 04, 20262.142.272.122.267.51M
Apr 30, 20262.132.172.112.135.02M
Apr 29, 20262.182.222.092.116.5M
Apr 28, 20262.262.302.182.196.23M
Apr 27, 20262.302.392.232.256.52M
Apr 23, 20262.382.412.272.359.36M
Apr 22, 20262.352.502.312.399.41M
Apr 21, 20262.422.432.232.328.71M
Apr 20, 20262.372.562.352.4212.03M
Apr 17, 20262.402.532.342.3911.52M
Apr 16, 20262.232.502.212.3728.78M
Apr 14, 20263.033.082.242.2841.38M
Apr 13, 20264.094.463.013.0687.26M
Apr 10, 20262.952.952.612.727.29M
Apr 09, 20262.722.912.702.914.8M
Apr 08, 20262.752.822.592.703.57M

Contact Details

South San Francisco, CA 94080

United States

https://www.allogene.com650 457 2700

About Company

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Company Information

Employees226
Beta0.5
Sales or Revenue$95.00K
5Y Sales Change%0%
Fiscal Year EndsDecember
SectorHealthcare
IndustryBiotechnology

Stock Peers

ARGX
-5.14-0.65%
argenx SE$782.17REGN
5.79+0.82%
Regeneron Pharmaceuticals, Inc.$714.89UTHR
-4.24-0.74%
United Therapeutics Corporation$564.94MDGL
-24.82-4.64%
Madrigal Pharmaceuticals, Inc.$510.04VRTX
4.82+1.13%
Vertex Pharmaceuticals Incorporated$429.82PRAX
-3.26-0.98%
Praxis Precision Medicines, Inc.$330.02KRTX
0.09+0.03%
Karuna Therapeutics, Inc.$329.83KRYS
9.01+3.04%
Krystal Biotech, Inc.$305.71ALNY
-0.86-0.29%
Alnylam Pharmaceuticals, Inc.$295.05ASND
-7.48-3.04%
Ascendis Pharma A/S$238.66

Company Overview

Allogene Therapeutics, Inc. (NASDAQ:ALLO) closed at $2.28 USD, gaining $0.01 (0.44%) from the previous close of $2.27. The stock is currently mid-range between its 52-week high and low $0.86 and $4.46. With a market capitalization of about $556.02 million, Allogene Therapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.46). Key stats such as the average daily volume over the past year has been around 9.35 million shares, volume is running light vs its 52-week average. Headquartered in South San Francisco, CA, Allogene Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David D. Chang, the company employs approximately 226 people and listed since October 11, 2018. Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 40.54%, SMA50 62.62%, SMA200 102.72%). The stock’s 14-day RSI is 75.84 (overbought), while the ATR of 0.18 points to higher daily volatility. The stock remains hovering near 52-week lows, trading 6.43% below its high and over 216.67% above its low. Average 10-day trading volume of 6.05 million shares is below the 3-month average of 8.45 million, indicating normal recent market interest.

Valuation Metrics

Allogene Therapeutics, Inc. trades at a P/E ratio of -2.63, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.72 suggesting the stock is closer to book value. The P/FCF stands at -3.71, also below market averages.

Dividend & Fair Value

Allogene Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.11. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Allogene Therapeutics, Inc. generated EPS of -$0.98 over the past year. Five-year average earnings growth is 6.26%. Wall Street analysts project EPS growth of 14.79% annually over the next five years. The latest quarter delivered EPS of -$0.17. The next quarter is forecast at -$0.23. Next year's EPS is expected at $10.48. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 5 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $14.00 to $3.85. The high target offers 514.04% upside. The low target suggests 68.86% downside. The mean target is $8.88. This offers 289.47% upside. Allogene Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended March 12, 2026, missed forecasts by -32.0%. The prior quarter beat by -17.39%. Over the last six quarters, Apple has recorded several small beats. These include -3.03% in November 07, 2024.

Shareholding & Insider Activity

Allogene Therapeutics, Inc. has 343.98 million shares outstanding. The public float is 190.43 million shares, elevated short interest at 17.69% of float. This equals 36.38 million shares. The short ratio is 2.51 days. Institutional investors hold 75.62% of the float. Insiders own 16.7%. TPG Group Holdings (SBS) Advisors, Inc. holds 18.72 million shares, Chang David D has 5.15 million shares and Belldegrun Arie has 1.72 million shares. Over the past six months, insider transactions show net selling. They sold 288.82 thousand shares across 13 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Allogene Therapeutics generated $95.00K in revenue, or $0.00 per share. Gross margin was -255598.95%, operating margin -331044.21%, and net profit margin -344489.47%. Returns are negative, with ROA at -50.91% and ROE at -63.89%.
On valuation metrics, Allogene Therapeutics trades at a P/E of -2.63, P/S of 0.00 and P/B of 1.72. The current ratio is 7.93 and quick ratio is 7.93. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -41.76 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.28, supported by a cash flow-to-debt ratio of -1.79.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Allogene Therapeutics posted revenue of $95.00K, down slightly from $243.00K in the prior quarter. Gross profit was - $242.82M (margin -255598.95%). Operating income was - $314.49M (margin -331044.2%). Net income was- $327.27M (EPS - $2.09).
The company ended the quarter with $448.70M in cash and short-term investments, a total debt of $95.12M, and net debt of $11.97M. Total assets were $642.84M, with equity of $512.23M. Financials further reflected weakness, with operating cash flow of - $237.73M, free cash flow of - $239.25M, and capital expenditures of - $1.52M.

Frequently Asked Questions

What is the current Allogene Therapeutics, Inc. (ALLO) stock price?
Allogene Therapeutics, Inc. (NASDAQ: ALLO) stock price is $2.28 in the last trading session. During the trading session, ALLO stock reached the peak price of $2.36 while $2.25 was the lowest point it dropped to. The percentage change in ALLO stock occurred in the recent session was 0.44% while the dollar amount for the price change in ALLO stock was $0.01.
ALLO's industry and sector of operation?
The NASDAQ listed ALLO is part of Biotechnology industry that operates in the broader Healthcare sector. Allogene Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of ALLO?
Mr. Arun Balakumaran M.D., Ph.D.
Chief Medical Officer
Dr. Alison Moore Ph.D.
Chief Technical Officer
Dr. Eric Thomas Schmidt Ph.D.
Executive Vice President & Chief Financial Officer
Mr. Veer Bhavnagri
Gen. Counsel & Compliance Officer
Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D.
Co-Founder & Executive Chairman
Dr. David D. Chang M.D., Ph.D.
Co-Founder, Pres, Chief Executive Officer & Director
Mr. Joshua A. Kazam
Co-Founder & Director
Mr. Timothy L. Moore Ph.D.
Executive Vice President & Chief Technical Officer
Ms. Barbra Sasu
Chief Scientific Officer
Mr. Stephen Cheng
Chief Information Officer
Ms. Lillian Smith
Interim Gen. Counsel & Compliance Officer
Ms. Christine Cassiano
Chief Communications Officer
Ms. Susan R. Lundeen
Chief People Officer
Ms. Diane Hagerty
Senior Vice President of Quality
Dr. Rafael G. Amado M.D.
Pres and Head of Global Oncology R&D
How ALLO did perform over past 52-week?
ALLO's closing price is 165.12% higher than its 52-week low of $0.86 where as its distance from 52-week high of $4.46 is -48.88%.
How many employees does ALLO have?
Number of ALLO employees currently stands at 226.
Link for ALLO official website?
Official Website of ALLO is: https://www.allogene.com
How do I contact ALLO?
ALLO could be contacted at phone 650 457 2700 and can also be accessed through its website. ALLO operates from 210 East Grand Avenue, South San Francisco, CA 94080, United States.
How many shares of ALLO are traded daily?
ALLO stock volume for the day was 4.47M shares. The average number of ALLO shares traded daily for last 3 months was 9.35M.
What is the market cap of ALLO currently?
The market value of ALLO currently stands at $556.02M with its latest stock price at $2.28 and 243.87M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

HomeAboutMeet The TeamContact UsPrivacy PolicyNewsletter

Useful Links

ScreenerMarket DataInsider TransactionsUpgrades & Downgrades52 Week Highs & LowsUnusual VolumeDividend CalendarEarnings CalendarStocks Watchlist
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph